ReviewRapid-Acting Glutamatergic Antidepressants: The Path to Ketamine and Beyond
Section snippets
N-Methyl-D-Aspartate Receptor Antagonists as Rapid-Acting Antidepressants
The testing of glutamatergic drugs for the treatment of depression has a surprisingly long history. In 1959, Dr. George Crane reported on the effects of a tuberculosis antibiotic that was known to cause seizures and exacerbate psychosis, D-cycloserine. In his first case series, he found that D-cycloserine produced mood improvement in 30 of 37 tuberculosis patients suffering from depression, predominately within 2 weeks (10). When he replicated these findings in another case series, he
Glutamate and the Neurobiology of Depression
Glutamatergic neurotransmission emerged over a decade ago as an extremely important area for depression research (91). This progress was inevitable as glutamate neurons are important targets for monoamine systems previously implicated in depression neurobiology and treatment, cortical neuroimaging studies in depression describe alterations in glutamatergic connectivity, and glutamatergic functional connectivity is targeted by both psychotherapeutic and neurostimulation treatments for depression
From Glutamate Pathophysiology to Novel Therapeutics
This model of glutamate synaptic dysfunction in depression yields a number of testable hypotheses regarding the treatment of this disorder. Studies support the hypothesis that immunologic activation, perhaps mediated by glial dysfunction, contributes to the emergence of depression-like states that are responsive to the effects of NMDA receptor antagonists. For example, NMDA receptor antagonists appear to treat fatigue and dysphoric mood associated with multiple sclerosis and interferon
Discussion
Research on rapid-acting antidepressants is shaping expectations regarding what might be achieved through antidepressant treatment. Ketamine research has proved to unlock new insights into the neurobiology of depression and to point to new and otherwise unexpected classes of antidepressant medications. Fifty years of antidepressant research suggested that antidepressants needed to act on monoamine systems and that treatment required weeks to months to produce benefits in responding patients. It
References (127)
- et al.
Signaling pathways underlying the rapid antidepressant actions of ketamine
Neuropharmacology
(2012) The psychotropic effect of cycloserine: A new use of an antibiotic
Compr Psychiatry
(1961)- et al.
Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine
Neuropharmacology
(2001) - et al.
Amantadine in depression
Lancet
(1971) - et al.
Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents—preclinical studies
Neurosci Biobehav Rev
(1997) - et al.
Glutamate-based antidepressants: 20 years on
Trends Pharmacol Sci
(2009) - et al.
Functional antagonists at the NMDA receptor complex exhibit antidepressant actions
Eur J Pharmacol
(1990) - et al.
1-aminocyclopropanecarboxylates exhibit antidepressant and anxiolytic actions in animal models
Eur J Pharmacol
(1991) - et al.
Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715)
Pharmacol Biochem Behav
(1995) - et al.
Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock or imipramine
Eur J Pharmacol
(1993)